SG11201707920YA - Method for treating cancer - Google Patents

Method for treating cancer

Info

Publication number
SG11201707920YA
SG11201707920YA SG11201707920YA SG11201707920YA SG11201707920YA SG 11201707920Y A SG11201707920Y A SG 11201707920YA SG 11201707920Y A SG11201707920Y A SG 11201707920YA SG 11201707920Y A SG11201707920Y A SG 11201707920YA SG 11201707920Y A SG11201707920Y A SG 11201707920YA
Authority
SG
Singapore
Prior art keywords
treating cancer
cancer
treating
Prior art date
Application number
SG11201707920YA
Inventor
Nicholas Mcgranahan
Rachel Rosenthal
Charles Swanton
Karl Peggs
Sergio Quezada
Original Assignee
Cancer Research Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1507100.4A external-priority patent/GB201507100D0/en
Priority claimed from GBGB1603663.4A external-priority patent/GB201603663D0/en
Priority claimed from GBGB1603731.9A external-priority patent/GB201603731D0/en
Application filed by Cancer Research Tech Ltd filed Critical Cancer Research Tech Ltd
Publication of SG11201707920YA publication Critical patent/SG11201707920YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464401—Neoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/505—CD4; CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
SG11201707920YA 2015-04-27 2016-04-27 Method for treating cancer SG11201707920YA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1507100.4A GB201507100D0 (en) 2015-04-27 2015-04-27 Method
GBGB1603663.4A GB201603663D0 (en) 2016-03-02 2016-03-02 Method
GBGB1603731.9A GB201603731D0 (en) 2016-03-03 2016-03-03 Method
PCT/EP2016/059401 WO2016174085A1 (en) 2015-04-27 2016-04-27 Method for treating cancer

Publications (1)

Publication Number Publication Date
SG11201707920YA true SG11201707920YA (en) 2017-11-29

Family

ID=55809140

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201707920YA SG11201707920YA (en) 2015-04-27 2016-04-27 Method for treating cancer
SG10202007364RA SG10202007364RA (en) 2015-04-27 2016-04-27 Method for treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202007364RA SG10202007364RA (en) 2015-04-27 2016-04-27 Method for treating cancer

Country Status (22)

Country Link
US (3) US20180064793A1 (en)
EP (4) EP3288581B1 (en)
JP (4) JP6918703B2 (en)
KR (2) KR20230125090A (en)
CN (2) CN117467603A (en)
AU (2) AU2016256220B2 (en)
BR (1) BR112017020893A2 (en)
CA (1) CA2982266A1 (en)
CL (2) CL2017002728A1 (en)
DK (1) DK3288581T3 (en)
ES (1) ES2836273T3 (en)
HU (1) HUE052106T2 (en)
IL (2) IL298497A (en)
MX (1) MX2017013777A (en)
MY (1) MY189338A (en)
NZ (1) NZ735882A (en)
PL (1) PL3288581T3 (en)
PT (1) PT3288581T (en)
RU (2) RU2020123735A (en)
SG (2) SG11201707920YA (en)
WO (1) WO2016174085A1 (en)
ZA (1) ZA201706616B (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
TWI765875B (en) 2015-12-16 2022-06-01 美商磨石生物公司 Neoantigen identification, manufacture, and use
US20170224796A1 (en) 2016-02-05 2017-08-10 Xeme Biopharma Inc. Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
TWI826360B (en) * 2016-11-17 2023-12-21 美商艾歐凡斯生物治療公司 Remnant tumor infiltrating lymphocytes and methods of preparing and using the same
US11276479B2 (en) 2016-12-01 2022-03-15 Nantomics, Llc Tumor antigenicity processing and presentation
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
AU2018218221A1 (en) * 2017-02-07 2019-08-15 Memorial Sloan Kettering Cancer Center Use of immune checkpoint modulators in combination with antigen-specific T cells in adoptive immunotherapy
TWI672503B (en) 2017-03-31 2019-09-21 行動基因生技股份有限公司 Ranking system for immunogenic cancer-specific epitopes
WO2019012296A1 (en) 2017-07-14 2019-01-17 The Francis Crick Institute Limited Analysis of hla alleles in tumours and the uses thereof
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. Neoantigen identification using hotspots
CA3083097A1 (en) 2017-11-22 2019-05-31 Gritstone Oncology, Inc. Reducing junction epitope presentation for neoantigens
EP3844776A1 (en) * 2018-08-28 2021-07-07 CeCaVa GmbH & Co. KG Methods for ranking and/or selecting tumor-specific neoantigens
EP3618071A1 (en) * 2018-08-28 2020-03-04 CeCaVa GmbH & Co. KG Methods for selecting tumor-specific neoantigens
CN109337873A (en) * 2018-09-30 2019-02-15 北京鼎成肽源生物技术有限公司 A kind of LRFF cell
CN109295097B (en) * 2018-09-30 2020-09-25 北京鼎成肽源生物技术有限公司 MRFFT2 cell
CN109294997B (en) * 2018-09-30 2020-09-25 北京鼎成肽源生物技术有限公司 LRFFT1 cell
CN109485721A (en) * 2018-11-23 2019-03-19 杜学明 A method of obtaining tumor specific T cells receptor
AU2020204779A1 (en) * 2019-01-03 2021-08-26 Evaxion Biotech A/S Vaccines targeting neoepitopes
CN110534156B (en) * 2019-09-02 2022-06-17 深圳市新合生物医疗科技有限公司 Method and system for extracting immunotherapy new antigen
CN110689930B (en) * 2019-10-18 2021-07-30 北京橡鑫生物科技有限公司 Method and device for detecting TMB
WO2021087839A1 (en) * 2019-11-07 2021-05-14 武汉华大吉诺因生物科技有限公司 Tumor-specific polypeptide sequence and application thereof
WO2021116714A1 (en) * 2019-12-12 2021-06-17 Achilles Therapeutics Uk Limited Method for obtaining nucleic acid for sequencing
CA3164986A1 (en) 2019-12-20 2021-06-24 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
US20230235008A1 (en) * 2020-02-14 2023-07-27 H. Lee Moffitt Cancer Center And Research Institute, Inc. Novel t cell receptors (tcrs) that react to neoantigens
CN111303268B (en) * 2020-03-10 2021-08-27 江苏兰恩生物治疗技术研究院有限公司 Hysteromyoma neoantigen, application thereof and hysteromyoma vaccine
US20230193203A1 (en) * 2020-04-30 2023-06-22 The Translational Genomics Research Institute Neoantigen-informed tumor-infiltrating lymphocyte cancer immunotherapy
JP7537930B2 (en) 2020-07-28 2024-08-21 株式会社ミツトヨ Shape measurement method
GB202104715D0 (en) * 2021-04-01 2021-05-19 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
GB202202880D0 (en) 2022-03-02 2022-04-13 Achilles Therapeutics Uk Ltd Methods for peptide synthesis
WO2023194491A1 (en) 2022-04-07 2023-10-12 The Francis Crick Institute Limited Analysis of hla alleles transcriptional deregulation
GB202205147D0 (en) 2022-04-07 2022-05-25 Achilles Therapeutics Uk Ltd Identification of clonal neoantigens and uses thereof
GB202205135D0 (en) 2022-04-07 2022-05-25 Francis Crick Institute Ltd Analysis of HLA alleles transcriptional deregulation
GB202210006D0 (en) 2022-07-07 2022-08-24 Achilles Therapeutics Uk Ltd Analysis of T cell samples
WO2024034622A1 (en) * 2022-08-08 2024-02-15 北海道公立大学法人 札幌医科大学 Method for selecting subject-derived neoantigen
GB202213928D0 (en) 2022-09-23 2022-11-09 Achilles Therapeutics Uk Ltd Allele specific expression
WO2024194208A1 (en) 2023-03-17 2024-09-26 Achilles Therapeutics Uk Limited Prediction of immunogenicity
CN117535352B (en) * 2023-10-16 2024-07-26 同济大学 Method for screening T cells with POLE antigen specificity

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2209633C2 (en) * 1997-09-19 2003-08-10 Юниверсити Оф Саузерн Калифорниа T-cellular vaccine for cerebrospinal sclerosis treatment
AU3483001A (en) * 2000-02-04 2001-08-14 Corixa Corp Compositions and methods for the therapy and diagnosis of ovarian cancer
CN105648056A (en) * 2010-05-14 2016-06-08 综合医院公司 Composite and method for detecting tumor specific novel antigen
HRP20230443T1 (en) * 2011-05-24 2023-09-15 BioNTech SE Individualized vaccines for cancer
AU2013289939B2 (en) * 2012-07-12 2018-08-09 Persimmune, Inc. Personalized cancer vaccines and adoptive immune cell therapies
EP2882867A1 (en) * 2012-08-10 2015-06-17 The Broad Institute, Inc. Methods and apparatus for analyzing and quantifying dna alterations in cancer
HUE050797T2 (en) 2012-10-10 2021-01-28 Sangamo Therapeutics Inc T cell modifying compounds and uses thereof
CA2908434C (en) * 2013-04-07 2021-12-28 The Broad Institute, Inc. Compositions and methods for personalized neoplasia vaccines
WO2015014375A1 (en) * 2013-07-30 2015-02-05 Biontech Ag Tumor antigens for determining cancer therapy
GB201319446D0 (en) * 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
WO2015095811A2 (en) * 2013-12-20 2015-06-25 The Board Institute Inc. Combination therapy with neoantigen vaccine
TWI755158B (en) * 2015-03-17 2022-02-11 德商英麥提克生物技術股份有限公司 Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
GB201516047D0 (en) * 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method

Also Published As

Publication number Publication date
CL2017002728A1 (en) 2018-06-22
EP4137151A1 (en) 2023-02-22
HUE052106T2 (en) 2021-04-28
US20180064793A1 (en) 2018-03-08
NZ735882A (en) 2022-07-29
IL298497A (en) 2023-01-01
CN117467603A (en) 2024-01-30
ES2836273T3 (en) 2021-06-24
JP2020127404A (en) 2020-08-27
EP3603666A1 (en) 2020-02-05
RU2017134504A (en) 2019-04-04
EP3288581A1 (en) 2018-03-07
RU2017134504A3 (en) 2020-08-12
AU2016256220A1 (en) 2017-10-19
ZA201706616B (en) 2021-03-31
RU2020123735A (en) 2020-07-30
DK3288581T3 (en) 2021-01-11
JP2022008381A (en) 2022-01-13
JP2018520637A (en) 2018-08-02
SG10202007364RA (en) 2020-09-29
KR102629590B1 (en) 2024-01-24
KR20230125090A (en) 2023-08-28
EP3603665A1 (en) 2020-02-05
CA2982266A1 (en) 2016-11-03
US20200000903A1 (en) 2020-01-02
CN107750278B (en) 2023-10-03
RU2770447C2 (en) 2022-04-18
PL3288581T3 (en) 2021-05-31
EP3288581B1 (en) 2020-11-11
KR20170138560A (en) 2017-12-15
CL2020001730A1 (en) 2020-11-06
AU2021286241B2 (en) 2024-10-10
US20200000904A1 (en) 2020-01-02
AU2021286241A1 (en) 2022-01-06
IL254760B1 (en) 2023-01-01
JP2024001069A (en) 2024-01-09
IL254760B2 (en) 2023-05-01
IL254760A (en) 2017-12-31
CN107750278A (en) 2018-03-02
AU2016256220B2 (en) 2021-10-21
BR112017020893A2 (en) 2018-07-10
JP6918703B2 (en) 2021-08-11
MX2017013777A (en) 2018-03-27
MY189338A (en) 2022-02-04
PT3288581T (en) 2020-12-04
WO2016174085A1 (en) 2016-11-03

Similar Documents

Publication Publication Date Title
HK1251407A1 (en) Methods for treating cancer
IL304252A (en) Method for treating cancer
ZA201706616B (en) Method for treating cancer
IL289947A (en) Method for treating cancer
IL257691A (en) Method for treating cancer
EP3110509A4 (en) Method for treating cancer
HK1254258A1 (en) Methods for treating cancer using apilimod
HK1244217A1 (en) Methods for treating proteinopathies
HK1250944A1 (en) Methods for treating cancer
EP3389634A4 (en) Methods for treating cancer
HK1248135A1 (en) Combination method for treating cancer
EP3389652A4 (en) Methods for treating cancer
HK1250942A1 (en) Methods for treating cancer
HK1250943A1 (en) Methods for treating cancer
EP3247376A4 (en) Method for treating cancer
SG10201508795XA (en) Method for treating cancer
HK1256371A1 (en) Methods for treating tumours